SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Immunomedics (IMMU) - moderated
An SI Board Since September 2006
Posts SubjectMarks Bans Symbol
63388 357 15 IMMU
Emcee:  idahoranch1 Type:  Moderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
61043Some key points from other distinguished scientists in the field concerning Lesnghettogoulash-8/6/2022
61042Check out the comments from working scientists in the field. It is clear that thghettogoulash18/6/2022
61041AUPH Earnings Call Transcript seekingalpha.comdorightbythem18/4/2022
61040Will listen to the AUPH cc in the next few days. From the PR, I like the continallatwwk-8/4/2022
61039It was meh. No guidance No change on year end revenue projections Sale increasdorightbythem-8/4/2022
61038AUPH: I wasnt able to listen to the conf call this morning. Street seems to liplhky3465-8/4/2022
61037Is it possible for AUPH to amend their patent in a way as to not require reapplidorightbythem-8/3/2022
61036Just saw that enrollment is split evenly between the two trials. That changes myghettogoulash-8/3/2022
61035I was actually hoping to see a number like 400+. Some have compared enrollment oghettogoulash-8/3/2022
61034Maybe a red flag? Thoughts… Enrollment is so important and the rate also can srodneyh07-8/3/2022
61033I am underwhelmed with SAVA enrollment numbers. At this rate, it will take yearsscorman128/3/2022
61032Same sense about the SAVA data as jargonweary. The data was good, though perhaallatwwk18/3/2022
61031I feel pretty good about the data released by SAVA this morning. I am far from ajargonweary-8/3/2022
61030I apologize for calling Dr. Bordey a hack. She is not.ghettogoulash-8/3/2022
61029Clearly someone pointed out the $18k error. It is a non-issue and SAVA refiled Davidoff-8/3/2022
61028Gilead Notes from this quarter results: Turning to Oncology, and beginning withsummer_sky98/3/2022
61027I've been wondering why we would lend our drug out to someone else in the fighettogoulash-8/3/2022
61026Correction: Yale has renamed PTI-125 (Simufilam) as NT-125 in their pursuit of Ighettogoulash-8/3/2022
61025This is probably the final determination by the SEC of Cassava Sciences-- an $18ghettogoulash-8/3/2022
61024In a nutshell, "Amyloid drugs" remove already formed plaques with dubighettogoulash-8/3/2022
61023The issue of Aduhelm is that the FDA decided to approve the drug based on it fitallatwwk28/3/2022
61022That's great news! Congrats to you as well.ghettogoulash-8/3/2022
61021This article has nothing to do with Cassava Sciences, only that this "sleutghettogoulash18/3/2022
61020Simufilam history: From research funded by Cassava Sciences (then Pain Therapeutscorman118/2/2022
61019Yes, I agree that it would be very difficult for someone in the FDA to just killOlecranon-8/1/2022
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News